B-Myb is a highly conserved member of the Myb family of transcription factors whose activity is regulated during the cell cycle. Previous work has shown that the activity of BMyb is stimulated by cyclin A/Cdk2-dependent phosphorylation whereas interaction of B-Myb with cyclin D1 inhibits its activity. Here, we have investigated the role of p300 as a coactivator for B-Myb. We show that B-Mybdependent transactivation is stimulated by p300 as a result of interaction between B-Myb and p300. We have mapped the sequences responsible for the interaction of B-Myb and p300 to the E1A-binding region of p300 and the transactivation domain of B-Myb, respectively. Furthermore, our data suggest that phosphorylation of B-Myb stimulates its acetylation by p300 and that the acetylation of B-Myb is necessary for the full stimulation of its transactivation potential by p300. We have also studied the effect of cyclin D1 on the cooperation of B-Myb and p300. Based on our results we propose that cyclin D1 inhibits the activity of B-Myb by interfering with the interaction of B-Myb and p300. The data reported here provide novel insight into the mechanisms by which the activity of B-Myb is regulated during the cell cycle. Taken together they suggest that the coactivator p300 plays an important role in this regulation and that the cooperation of B-Myb and p300 is orchestrated by cyclins A and D1.
Introduction
The initiation of transcription by RNA polymerase II is a highly regulated process in which the cooperation of DNA-binding transcription factors with the basal transcriptional machinery and the modulation of chromatin structure play crucial roles. In recent years transcriptional coactivators such as p300 and the CREB-binding protein (CBP) have been recognized as key molecules involved in these processes (Janknecht and Hunter, 1996; Giordano and Avantaggiati, 1999; Goodman and Smolik, 2000) . p300 was originally identified as a cellular interaction partner of the adenovirus E1A oncoprotein (Eckner et al., 1994) , which suppresses the transcriptional activation of certain promoters by interfering with the function of p300. p300 is highly related to CBP, first identified as a coactivator of CREB (Arany et al., 1995; Lundblad et al., 1995; Giordano and Avantaggiati, 1999) . p300 interacts with a broad spectrum of transcription factors such as CREB, Jun, c-Myb, A-Myb, Sap-1a/Elk-1, Fos, p53, MyoD, E2F and the nuclear hormone receptors (Chrivia et al., 1993; Arias et al., 1994; Chakravarti et al., 1996; Dai et al., 1996; Janknecht and Nordheim, 1996; Avantaggiati et al., 1997; Facchinetti et al., 1997; Gu et al., 1997; Martinez-Balbas et al., 2000) . p300 does not by itself interact with specific DNA sequences, rather it displays a variety of protein interaction surfaces that are thought to link specific transcription factors via protein-protein interactions to the basal transcriptional machinery. In addition, p300/CBP has intrinsic histone acetyltransferase activity, which enables the protein to cause localized changes in the chromatin structure of genes to which it is targeted via interaction with specific transcription factors (Bannister and Kouzarides, 1996; Ogryzko et al., 1996; Tsukiyama and Wu, 1997) . The acetyltransferase activity of p300/CBP is not restricted to histones as p300 has been shown to modulate the functions of several transcription factors by acetylating them (Imhof et al., 1997) . For example, the transcription factors c-Myb and E2F are acetylated by p300, leading to increased DNA-binding activity and, thus, to higher transactivation of target promotors (Martinez-Balbas et al., 2000; Marzio et al., 2000; Tomita et al., 2000) . Recent evidence indicates that the histone acetylase activity of the CBP is regulated during the cell cycle by phosphorylation at the G 1 /S-phase boundary (Ait-Si-Ali et al., 1998) . p300/CBP might therefore also play a specific role in the regulation of cell cycle progression (Ait-Si-Ali et al., 2000) .
The transcription factor B-Myb, a member of the myb proto-oncogene family (A-Myb, B-Myb and c-Myb) (Nomura et al., 1988; Bouwmeester et al., 1992; Foos et al., 1992; Lam et al., 1992) , is expressed in a wide variety of dividing cells and appears to have a general function during cell proliferation. B-myb expression is downregulated in quiescent fibroblasts and subsequent re-entry into the cell cycle induces expression of B-myb in the late G1/early S phase (Lam et al., 1992; Lam and Watson, 1993) . During mouse embryogenesis B-myb expression is tightly linked to the proliferative activity of cells and tissues (Sitzmann et al., 1996) . B-myb antisense oligonucleotides have been shown to inhibit cell proliferation (Arsura et al., 1992) . Whereas overexpression of B-myb enables cells to escape the cell cycle arrest that is induced by overexpression of the tumor suppressor protein p53 and mediated by the Waf1/ Cip1 protein (Lin et al., 1994) . The cell cycle regulated B-myb expression is dependent on an E2F-binding site within the B-myb promoter and involves negative regulation by E2F complexes (Lam and Watson, 1993; Zwicker et al., 1996) . Superimposed on the control of Bmyb mRNA expression the activity of the B-Myb protein is regulated by post-translational modification. Phosphorylation of B-Myb by cyclin A/Cdk2 in the early S phase of the cell cycle counteracts the repressive function of an inhibitory domain located at the carboxyl-terminus and thereby stimulates the transactivation potential of B-Myb (Robinson et al., 1996; Lane et al., 1997; Sala et al., 1997; Saville and Watson, 1998; Bartsch et al., 1999) . How this phosphorylationdependent stimulation of B-Myb activity is effected on the molecular level, has not been elucidated so far. In addition to stimulating B-Myb activity cyclin A/Cdk2-mediated phosphorylation leads to polyubiqitination of B-Myb, which directs it to rapid degradation by the 26S proteasome (Charrasse et al., 2000) . Recently, we showed that cyclin D1, in contrast to cyclin A, inhibits the function of B-Myb in a Cdk-independent manner by physically interacting with B-Myb (Horstmann et al., 2000a) . Thus, it seems clear that the activity of B-Myb is regulated in a complex manner around the G1/S-transition of the cell cycle, however, the molecular mechanisms by which cyclins A and D1 control B-Myb activity are not yet understood.
The finding that p300/CBP acts as coactivator for AMyb and c-Myb (Dai et al., 1996; Oelgeschlager et al., 1996; Facchinetti et al., 1997) has prompted us to investigate whether p300 plays a role in the regulation of B-Myb activity. Here, we show that p300 stimulates the activity of B-Myb by interacting with the transactivation domain of B-Myb located in the center of the protein.
We also show that p300 acetylates the C-terminal domain of B-Myb and that acetylation is required for full stimulation of the transactivation potential of B-Myb. Furthermore, our data suggest that cyclin D1 disrupts the interaction of B-Myb with p300. Our work, therefore, identifies p300 as a crucial player in the regulation of B-Myb activity by different cyclins.
Results

Stimulation of B-Myb-dependent transactivation by p300
To show that p300 acts as a coactivator for B-Myb and to delineate the domain of B-Myb, which mediates the stimulation by p300 we examined the activation of the Myb-responsive reporter gene pGL3-3xATk-Luc by full-length or various deleted versions of mouse BMyb in the presence or absence of p300. pGL3-3xATk-Luc contains three copies of a Myb-binding site fused to the thymidine kinase promoter and is widely used to monitor transactivation by Myb proteins. The reporter gene was cotransfected with different combinations of expression vectors for full-length or partially deleted BMyb, cyclin A and p300 into QT6 cells, a fibroblast line that has been used extensively to study Myb-dependent transactivation. Figure 1 shows that transactivation mediated by full-length B-Myb was increased by p300, both in the presence of cyclin A as well as in its absence. The C-terminal B-Myb deletion mutant B-Myb D3 was stimulated by p300 to similar extent as full-length BMyb, whereas the deletion mutant B-Myb DFsp was not The cooperation of B-Myb with the coactivator p300 S Schubert et al significantly affected by p300. As shown in Figure 1c , the levels of the B-Myb proteins were not altered by p300. Thus, the sequences that mediate the stimulatory effect of p300 are located in the central part of B-Myb.
Interaction of B-Myb and p300 in vivo
The stimulation of B-Myb activity by p300 suggested that both proteins interact with each other. To confirm this interaction and to map the domain of p300, which binds to B-Myb, we performed in vivo coimmunoprecipitation experiments of B-Myb and different parts of p300. Figure 2a shows an overview of the p300 subfragments used for these studies. Cells were transfected with the appropriate expression vectors, labeled with [
35 S]methionine and analysed by immunoprecipitation with B-Myb-and p300-specific antibodies. To precipitate the N-terminal fragment p300/1-1264 we used a rabbit polyclonal antibody raised against the amino terminus of human p300 (Santa Cruz, . For immunoprecipitation of the C-terminal fragments of p300, p300/1515-1998 and p300/1853-2414, a mixture of monoclonal antibodies was used (UBI, antip300 #05-267). B-Myb was immunoprecipitated by a polyclonal rabbit antiserum raised against the DNAbinding domain of mouse B-Myb (Kamano et al., 1995) . As shown in Figure 2b , the C-terminal fragment of p300, p300/1515-1998, was coprecipitated by the B-Myb-specific antiserum in the presence of B-Myb (lane 15) but not in its absence (lane 12). Vice versa, B-Myb could be coprecipitated by the p300-specific antibody in the presence (lane 7) but not in the absence of p300/1515-1998 (lane 7). These controls show that the observed coprecipitation of B-Myb and p300/1515-1998 was not caused by crossreactivity of the antisera or by insufficient washing of the immunoprecipitates. A C-terminal fragment of p300 lacking the E1A-binding domain (p300/1853-2414) as well as the N-terminal fragment of p300 containing the CREB-binding domain (p300/1-1264) were not coprecipitated with B-Myb. Likewise, coprecipitation of B-Myb was not observed in the presence of p300/1-1264 or p300/1853-2414. Taken together, these observations show that B-Myb binds to sequences around the E1A-binding domain of p300.
To confirm the interaction between B-Myb and the E1A-binding region of p300 we investigated whether overexpression of the B-Myb-binding region of p300 (amino acids 1515-1998) on its own inhibits B-Mybmediated transactivation. Such an inhibition is expected to occur as a result of competition of the exogenously expressed p300 fragment with endogenous p300 for binding to B-Myb. As illustrated in Figure 3a , expression of the p300 fragment indeed significantly inhibited transactivation of the Myb-responsive reporter gene pGL3-3xATk-Luc by full-length B-Myb and B-Myb-D3. B-Myb-DFsp has lower transactivation potential than B-Myb-D3, however, its residual activity was not inhibited by p300/1515-1998. This is consistent with the observation that the activity of B-Myb-DFsp was not increased by full-length p300 (Figure 1 ) as well as with the results of protein-binding experiments, which showed that B-Myb-DFsp does not interact with p300/ 1515-1998 (see below). Analysis of the amounts of the different B-Myb proteins indicated that the observed inhibition was not due to insufficient B-Myb expression in the presence of the p300 fragment (data not shown). Figure 3b shows that p300/1-1264 and p300/1853-2414, in contrast to p300/1515-1998, do not inhibit transactivation by B-Myb, consistent with the observation that these parts of p300 do not interact with B-Myb.
p300 interacts with the central region of B-Myb
To map the p300-interacting domain within B-Myb we performed protein-binding experiments in vitro. As shown schematically in Figure 4a we expressed different parts of B-Myb as bacterial GST fusion proteins. Comparable amounts of the different GST fusion proteins were immobilized on glutathione-sepharose and used for binding in vitro translated p300 constructs. In accordance with the results shown in Figures 1 and 3 the fusion protein GST/B-Myb-D3 bound to p300/1515-1998 while the fusion protein GST/B-Myb-DFsp failed to do so. As expected, p300/1853-2414 did not bind to any of the B-Myb constructs.
In another experiment, illustrated in Figure 4b , we used GST/p300 fusion proteins immobilized on glutathione-sepharose to pull-down B-Myb from an extract of cells transfected with expression vectors for B-Myb and cyclin A. The B-Myb-specific band appears as a doublet corresponding to phosphorylated and unphosphorylated B-Myb (marked by black and white The cooperation of B-Myb with the coactivator p300 S Schubert et al arrows in Figure 4b ). This experiment shows that BMyb binds to the GST/p300(1710-1891) fusion protein but not to GST itself or to a GST/p300 fusion protein. This experiment also shows that phosphorylated as well as unphosphorylated B-Myb bind with similar efficiency to p300. Taken together, the in vivo and in vitro binding experiments indicate that the central part of B-Myb interacts with amino acids 1710-1891 of p300.
Previous work has shown that c-Myb binds to the CREB-binding domain of p300 (Dai et al., 1996; Oelgeschlaeger et al., 1996) , in contrast to B-Myb which, as shown here, interacts with the E1A-binding domain of p300. To demonstrate that both Myb family members indeed interact differently with p300, extracts of cells transfected with c-Myb or B-Myb expression vector were subjected to in vitro binding assays using different GST/p300 fusion proteins. Figure 4c shows the result of this experiment. c-Myb indeed binds preferentially to GST/p300(1-672) and only weakly to GST/ p300(1710-1891). By contrast, B-Myb binds to GST/ p300(1710-1891) whereas binding to GST/B-Myb (1710-1891) is not detected.
To map the p300 interacting domain of B-Myb in more detail, we performed additional in vitro binding experiments illustrated in Figure 5 . We again immobilized GST/p300(1710-1891) or, as negative control, GST itself on glutathione sepharose and followed by incubation of the sepharose beads with extracts from cells transfected with various B-Myb constructs. Analysis of binding of C-terminal deletion mutants of B-Myb showed that deletion construct D3 and DEar bind as well as full-length B-Myb. Binding of the DApo mutant is reduced while the DFsp mutant binds extremely weaky (see left part of Figure 5 ). This suggests that the sequences required for interaction with p300 mainly map to the exon 9A region of B-Myb and possibly to the sequences immediately preceding exon 9A. To dissect this region in more detail, we also analysed the binding of a series of Gal4-B-Myb fusion proteins containing the part of B-Myb illustrated at the top of Figure 5 . This analysis is illustrated in the right part of Figure 5 . Taking the somewhat variable input amounts of the different proteins into account (see shorter exposure of the input lanes for comparison of the amounts of the different constructs) we concluded that B-Myb constructs D5 and D2 bind efficiently whereas the other constructs bind very weakly (D1 and D4) or not at all (D3). It therefore appears that B-Myb domain D2 is the primary interaction site for p300(1710-1891).
Acetylation of B-Myb by p300
By using antibodies that recognize acetylated lysine residues we found that coexpression of B-Myb and fulllength p300 leads to acetylation of B-Myb (Figure 6a ), confirming similar observations on the acetylation of BMyb by CBP (Bessa et al., 2001; Johnson et al., 2002) . The acetylation of B-Myb by p300 appeared to be very efficient because we could detect acetylated B-Myb in a total extract of cells transfected with expression vectors for B-Myb and p300. Interestingly, most of the acetylated B-Myb migrated slower than the bulk of B-Myb. It has been found before that cyclin A/Cdk2-mediated phosphorylation of B-Myb reduces its electrophoretic mobility in SDS-polyacrylamide gels (Robinson et al., 1996; . The observation that acetylation occurs preferentially on a slower-migrating form of B-Myb is interesting as it suggests a link between phosphorylation of B-Myb, The cooperation of B-Myb with the coactivator p300 S Schubert et al which activates its transactivation potential, and acetylation of the protein by p300. To investigate a potential correlation between phosphorylation and acetylation of B-Myb we coexpressed B-Myb, full-length p300 and, additionally, a dominant-negative form of cdk2, the Figure 4 Interaction of B-Myb and p300 in vitro. (a) A schematic illustration of GST/B-Myb fusion proteins is shown at the top. The B-Myb DNA-binding domain and the GST protein are marked by black and white boxes, respectively. GST fusion proteins (indicated below) were bound to glutathione-sepharose, incubated with in vitro translated p300/1515-1998 or p300/1853-2414, as indicated above each panel, and subjected to the GST pull-down assay. Lane 1 of each panel shows a fraction (one fifth) of the total radioactive protein used for each pull-down assay. The input and bound proteins were analysed by SDS-PAGE and autoradiography. (b) p300 and GST/p300 protein are shown schematically at the top. GST fusion proteins (as indicated below the lanes) were bound to glutathione-sepharose and incubated with extract from cells transfected with expression vector for B-Myb and cyclin A. Bound proteins were analysed by SDS-PAGE and Western blotting using B-Myb specific antiserum. Lane 1 shows a fraction of total cell extract used for each binding reaction. Black and white arrows mark the phosphorylated and unphosphorylated forms of B-Myb, respectively. (c) Aliquots of extracts from cells transfected with expression vectors for c-Myb (top panel) or B-Myb (bottom panel) were incubated glutathione-sepharose carrying equal amounts of GST/p300 fusion proteins, as indicated. Bound proteins were then analysed by SDS-PAGE and Western blotting using antibodies specific for c-Myb or B-Myb The cooperation of B-Myb with the coactivator p300 S Schubert et al kinase which in conjunction with cyclin A is responsible for phosphorylating B-Myb. Figure 6d shows that the expression of dominant-negative cdk2 indeed inhibits the acetylation of B-Myb. Control experiments (Figure 6b, c) confirmed that the amounts of p300 or B-Myb were not affected by dominant-negative cdk2. Since p300 itself is also a substrate of cyclin-dependent kinases (Ait-Si-Ali et al., 1998), we considered the possibility that the effect of dominant-negative cdk2 might be due to a general decrease of the acetyl-transferase activity of p300. To address this possibility we assessed the effect of dominant-negative cdk2 on the ability of p300 to acetylate c-Myb, another substrate of the acetyltransferase activity of p300 (Figure 6e, f) . c-Myb is not phosphorylated by a cyclin-dependent kinase and, consistent with this, the dominant-negative cdk2 had no effect on the acetylation of c-Myb. This control experiment therefore shows that the inhibition of B-Myb acetylation by dominant-negative cdk2 is a specific effect and not due to a general decrease in acetyl-transferase activity of p300.
To further explore a possible link between B-Myb phosphorylation and acetylation we made use of two phosphorylation site mutants of B-Myb, referred to as mut10 and mut15, in which 8 (mut10) or 12 (mut15) of the authentic in vivo cyclin A/Cdk2 phosphorylation sites of B-Myb have been mutated to alanines (Johnson et al., 2002) . Both mutants have been characterized before by Johnson et al. (2002) . Mut10 shows residual and mut15 shows no phosphorylation by cyclin A/Cdk2. The trancriptional activity of mut10 is reduced compared to wild-type (wt) B-Myb while mut15 is transcriptionally inactive. As shown in Figure 6g , all three 1-3) . A shorter exposure of lanes 1-3 is shown at the bottom
The cooperation of B-Myb with the coactivator p300 S Schubert et al B-Myb forms were expressed in similar amounts, however, in comparison to wt B-Myb the acetylation of mut15 by p300 was substantially reduced. This reduction was not due to impaired binding of mut15 to p300, as shown by the in vitro binding experiment illustrated in Figure 6h . Comparison of the binding of B-Myb wt, mut10 and mut15 to GST/p300(1710 GST/p300( -1891 showed that all three B-Myb proteins interact with p300 with similar efficiency. Taken together, the experiments illustrated in Figure 6g and h are in accord with the idea that phosphorylation of B-Myb greatly stimulates its acetylation by p300.
Acetylation increases the transactivation potential of B-Myb
To address the question of whether acetylation of BMyb is relevant for B-Myb-dependent transactivation we made use of a p300 HAT-domain mutant, p300HA-DI1485AL. In this mutant amino-acid residues 1485 and 1486 have been mutated from DI to AL (Hecht et al., 2000) . As shown in Figure 7a , the mutated version of p300 was expressed at the same level as the wt form p300 but had largely lost the ability to acetylate B-Myb, demonstrating that the acetylation of B-Myb depends on the HAT-activity of p300. Transactivation experiments (Figure 7b) showed that the HAT-domain mutant of p300 was still able to stimulate transactivation mediated by full-length B-Myb, however, the stimulation was only approximately half as strong as in case of wt p300. Since the wt and the mutant p300 protein were both expressed at similar levels, this suggests that at least part of the stimulatory effect of p300 is dependent on the HAT activity of p300.
To explore whether the HAT activity of p300 is required for the acetylation of B-Myb itself or for the acetylation of other proteins assembled at the promoter (such as histones) we first sought to identify a variant of B-Myb that was not acetylated by p300. We therefore analysed the acetylation of deletion mutants of B-Myb by p300 (Figure 8a) . We found that the B-Myb mutants DFsp, DEar and D3 were not detectably acetylated. By contrast, the mutant DSac was acetylated, however, its acetylation was less efficient than the acetylation of fulllength B-Myb. This suggested that there are at least two acetylation sites in B-Myb, located between the Cterminal ends of the D3 and DSac constructs (amino acids 508-561) and carboxyterminally of the DSac construct (amino acid 561), respectively. To investigate whether the HAT activity of p300 is required for the acetylation of B-Myb (as opposed to the acetylation of histones) we made use of the B-Myb-DEar mutant, which is not detectably acetylated by p300. If the diminished activity of the p300 HAT-domain mutant was due to a lack of acetylation of B-Myb we would expect the stimulation of the activity of the DEar mutant by p300 to be HAT independent (i.e. wt p300 and the p300 HAT-domain mutant should stimulate the activity of B-Myb-DEar to the same extent). If, on the other hand, the reduced activity of the p300 HAT-domain mutant was due to lack of acetylation of histones, the stimulation of the activity of the DEar mutant should still be HAT dependent, even though B-Myb-DEar itself is not acetylated. The results of these experiments are illustrated in Figure 8b . It is apparent that the stimulation of the activity of B-Myb-DEar by p300 does not require the HAT activity of p300, clearly arguing in favour of the first possibility. Figure 8c shows that these conclusions were not compromised by differences in the amounts of B-Myb or p300. Together, these observations are consistent with the idea that p300 stimulates the activity of B-Myb by HAT dependent as well as HAT-independent mechanisms and that the HATdependent mechanisms involve the acetylation of lysine residues in the C-terminal part of B-Myb.
Cyclin D1 blocks the acetylation of B-Myb by p300
Previously, we have demonstrated that cyclin D1, in contrast to cyclin A/Cdk2, acts as an inhibitor of BMyb-mediated transactivation. The inhibitory effect of cyclin D1 was found to be Cdk independent but to depend on an interaction between cyclin D1 and B-Myb (Horstmann et al., 2000a) . Since the domain of B-Myb that interacts with cyclin D1 maps to the center of BMyb we considered the possibility that the inhibitory effect of cyclin D1 is due to a displacement of the coactivator p300 from B-Myb. To address this possibility we first examined the effect of cyclin D1 on the acetylation of B-Myb by full-length p300. As shown in Figure 9a in the presence of cyclin D1 the p300-dependent acetylation of B-Myb was strongly suppressed. A control Western blot showed that the amount of B-Myb was not decreased in the presence of cyclin D1 (data not shown). Although this result was consistent Figure 9b shows that in the absence of cyclin D1 B-Myb was coprecipitated with p300/1515-1998 (lane 1). However, in the presence of cyclin D1 coprecipitation of BMyb and p300 was less efficient (lane 2), suggesting that cyclin D1 interferes with the interaction of B-Myb and p300. Control immunoprecipitations with B-Myb antiserum (middle panel of Figure 9b ) showed that similar amounts of B-Myb were expressed in the absence or presence of cyclin D1, indicating that the decrease in the amount of coprecipitated B-Myb was not due to a general decrease in the amount of B-Myb expressed. In fact, B-Myb was expressed even slightly higher in the presence of cyclin D1, yet it coprecipitated with p300 less efficiently in the presence of cyclin D1 than in its absence.
To corroborate these findings we also performed in vitro binding studies similar to those illustated in Figure 4b . Extracts from cells transfected with different combinations of expression vectors for B-Myb and cyclin D1 were incubated with GST/p300 fusion proteins immobilized on glutathione-sepharose, followed by analysis of bound proteins. Consistent with the results shown in Figure 4b , B-Myb specifically bound to GST/p300(1710-1891) but not to GST/ p300(1883 GST/ p300( -1927 or to GST alone (Figure 10 ). Interestingly, in the presence of cyclin D1 the amount of B-Myb interacting with GST/p300 that was substantially reduced (see panel e). As shown by the control Western blot in panel (a) this reduction was not due to a reduction in the total amount of B-Myb present in the different extracts. Thus, the in vivo and in vitro binding experiments shown in Figure 9 and 10 are fully consistent with each other and strongly suggest that cyclin D1 interferes with the binding of p300 to B-Myb. an important role in cell proliferation. B-Myb expression and function during the cell cycle is tightly controlled by multiple mechanisms. On the posttranslational level, B-Myb activity is stimulated by cyclin A/Cdk2-mediated phosphorylation and inhibited in a Cdk-independent manner by cyclin D1. In addition, several B-Myb interacting proteins have been identified and shown to modulate B-Myb activity. In the work described here we have studied the role of one of these interacting proteins, the coactivator p300 in more detail. The cooperation of B-Myb with the coactivator p300 S Schubert et al
p300 is a coactivator for B-Myb
The results presented here identify p300 as a bona fide coactivator for B-Myb. p300 stimulates the transactivation mediated by B-Myb and interacts with the part of B-Myb (referred to as domain D2), which has previously been shown to harbor the B-Myb transactivation domain (Horstmann et al., 2000b) . Furthermore, the C-terminal domain of p300, which is the relevant part of p300 interacting with B-Myb, acts as a dominantnegative inhibitor of B-Myb-mediated transactivation when expressed on its own. Our work is in accordance with previous reports that have demonstrated an interaction of B-Myb with the p300-related coactivator CBP (Bessa et al., 2001; Johnson et al., 2002) . However, our data reveal novel aspects of the cooperation of BMyb and p300 and, thus, significantly extend these previous studies. Firstly, we have identified the E1A-binding domain of p300 as the part of p300 interacting with B-Myb. Using in vivo and in vitro mapping data we have shown that a small region of p300, located between amino acids 1710 and 1891, is sufficient for interaction with B-Myb. This region of p300 interacts with a number of different proteins that raises the interesting possibility that the binding of some of these proteins will interfere with each other, thereby providing a means for crosstalk between different transcription factors. The interaction of B-Myb with the E1A-binding region of p300 is also interesting with respect to A-Myb and c-Myb, both of which also recruit p300 or CBP as coactivator (Dai et al., 1996; Oelgeschlager et al., 1996; Facchinetti et al., 1997) . The transactivation domains of A-Myb and c-Myb are highly related to each other but have no sequence similarity to the transactivation domain of B-Myb. A-Myb and c-Myb interact with the CREB-binding domain of p300/CBP (Dai et al., 1996; Oelgeschlager et al., 1996; Facchinetti et al., 1997) while B-Myb interacts with the E1A-binding domain of the coactivator, as shown here. Thus, the manner by which p300 is recruited is different for B-Myb versus A-Myb and cMyb, showing that members of the same transcription factor family can cooperate with the same coactivator in different ways.
Secondly, although the interaction between p300 and B-Myb appears to be independent of cyclin A/Cdk2-mediated phosphorylation of B-Myb (as previously also reported for the binding of B-Myb to CBP; Bessa et al., 2001) , our data raise the interesting possibility that the cooperation between p300 and B-Myb is affected by cyclin A/cdk2-mediated phosphorylation of B-Myb. The reporter gene assays illustrated in Figure 1 clearly show that the effects of cyclin A and p300 on B-Myb activity are synergistic. Furthermore, the analysis of the acetylation of B-Myb by p300 provides additional indirect evidence for the idea that the cooperation between p300 and B-Myb is stimulated by cyclin A/cdk2-mediated phosphorylation of B-Myb. This conclusion is based on the observations that (i) a dominant-negative version of Cdk2 inhibits acetylation by p300 and that (ii) acetylation of the phosphorylation site mutant mut15 of B-Myb is strongly reduced. As pointed out before virtually all of the authentic in vivo phosphorylation sites for cyclin A/ Cdk2 have been mutated in B-Myb mutant mut15. Hence, the reduced acetylation of this mutant is consistent with the notion that the cooperation between B-Myb and p300 is affected by cyclin A/Cdk2-mediated phosphorylation of B-Myb. Although the possibility that the amino-acid changes in mut15 have affected the conformation of the protein in addition to eliminating phosphorylation sites cannot be completely excluded, the fact that mut15 still interacts with p300 argues at least against gross conformational changes. Our results are at variance with those of Johnson et al. (2002) who have also analysed the acetylation of this mutant and, based on their results, have concluded that B-Myb acetylation does not depend on phosphorylation. However, their analysis only focuses on the acetylation of proteins but lacks controls of the amounts of B-Myb-wt, mut15 and p300, which makes it somewhat difficult to draw quantitative conclusions. How could phosphorylation of B-Myb affect its acetylation by p300? Since there is no evidence that p300 preferentially interacts with phosphorylated B-Myb, we suspect that there is a conformational shift of the C-terminal domain of B-Myb upon phosphorylation which exposes acetylatable sites on B-Myb which are not accessible to p300 in unphosphorylated B-Myb. Another possibility is that the C-terminus of unphosphorylated B-Myb is blocked by association with another protein. This model could possibly also explain the apparent discrepancy of our results and those of Johnson et al. (2002) . They have used different cell lines from the ones we have used and it is possible that these lines differ in the amounts of such blocking proteins. A possible candidate for such a protein is the corepressor N-CoR that has recently been shown to associate with the C-terminal domain of unphosphorylated but not of phosphorylated B-Myb (Li and McDonnell, 2002) . The acetylation sites in B-Myb are located in the C-terminal region of the protein that is also consistent with the mapping of the sites of CBPinducible acetylation in c-Myb (Tomita et al., 2000; Sano and Ishii, 2001) .
Thirdly, the work reported here also provides novel insight into the role of B-Myb acetylation. By using a mutant of p300 that no longer acetylates B-Myb we have shown that the stimulation of the activity of BMyb by p300 involves both acetylation-dependent and acetylation-independent mechanisms. Acetylationindependent mechanisms might involve a bridgeing function of p300 linking B-Myb to the basal transcription machinery or the recruitment of other proteins that bind to p300 and stimulate B-Myb activity. It is also clear from our data that the acetylation of B-Myb itself is required for maximal stimulation of B-Myb activity by p300. Our experiments furthermore show that the acetylation of B-Myb induced by p300 is mediated by p300 itself and not by an associated acetyl transferase.
The cooperation of B-Myb with the coactivator p300 S Schubert et al Cyclin D1 disrupts the B-Myb/p300 interaction Besides characterizing p300 as a coactivator for B-Myb a second major finding of our studies concerns the role of cyclin D1 in the regulation of B-Myb activity. Cyclin D1 is a G1 phase cyclin whose interaction with cyclindependent kinases (Cdk4 and Cdk6) supports transition through the G1 phase of the cell cycle by phosphorylation of the retinoblastoma protein, an inhibitor of the transcription factor E2F (Draetta, 1994; Sherr, 1995a, b; Weinberg, 1995) . Recent evidence shows that cyclin D1 also functions in a Cdk-independent way, suggesting that its role in the cell cycle is more complex (Bernards, 1999) . Cyclin D1 blocks myogenic differentiation by inhibiting the activity of myogenic transcription factors, such as MyoD and myogenin (Skapek et al., 1995 (Skapek et al., , 1996 . Furthermore, cyclin D1 forms a complex with the estrogen receptor resulting in estrogen-independent activation of the receptor (Neuman et al., 1997; Zwijsen et al., 1997) . Recently, cyclin D1 has also been found to inhibit the transcription factor BETA2/NeuroD in a Cdk-independent manner (Ratineau et al., 2002) . As far as Myb or Myb-related proteins are concerned, cyclin D1 has been demonstrated to inhibit DMP1-and v-Myb-mediated transactivation (Hirai and Sherr, 1996; Ganter et al., 1998; Inoue and Sherr, 1998) . Finally, we have shown previously that cyclin D1 inhibits the activity of B-Myb in a Cdk-independent manner by physically interacting with B-Myb (Horstmann et al., 2000a) . The novel results presented here raise the possibility that the inhibition of B-Myb activity by cyclin D1 is due to a displacement of the coactivator p300 from B-Myb. Our data clearly show that the acetylation of B-Myb by p300 as well as the binding of p300 to B-Myb is diminished in the presence of cyclin D1. These observations could be explained by a model in which cyclin D1 and p300 compete for binding to BMyb. A similar mechanism was proposed for the inhibitory effect of cyclin D1 on STAT3. It was found that cyclin D1 interacts with the activation domain of STAT3, thereby occluding this domain and blocking its interaction with the RNA polymerase II transcriptional machinery or with essential coactivators such as CBP/ p300 (Bienvenu et al., 2001) .
In summary, our data suggest a model in which the cooperation of p300 and B-Myb is orchestrated by the effects of cyclins D1 and A. Cyclin D1 in the G1 phase of the cell cycle presumably binds to B-Myb and thereby prevents its interaction with p300 resulting, in repression of the transactivation potential of B-Myb. Subsequently cyclin D1 is phosphorylated at threonine 286 mediated by the phosphatidylinositol-3-OH kinase (PI-3 K)/protein kinase B (PKB)/glycogen synthase kinase-3b (GSK3b) pathway and targeted to the cytosolic compartment where the protein is rapidly degraded (Diehl et al., 1998) . In the early S phase of the cell cycle B-Myb is phosphorylated by cyclin A/Cdk2 leading to increased B-Myb activity due to the inactivation of the inhibitory C-terminus of B-Myb (Lane et al., 1997; Sala et al., 1997; Johnson et al., 1999) . The disappearance of cyclin D1 at the G1/S-boundary permits p300 to bind to B-Myb. The concommittant increase of cyclin A/Cdk2 leads to phosphorylation of B-Myb followed by preferential acetylation of phosphorylated B-Myb and stimulation of its transactivation potential. The recent finding that cyclin A/Cdk2-induced phosphorylation of B-Myb disrupts the interaction of B-Myb with the corepressor N-CoR can easily be accommodated in this model (Li and McDonnell, 2002) . Thus, activation of B-Myb by cyclin A/Cdk2 apparently not only involves in increase in the interaction with a stimulatory factor (p300) but also a decrease of an inhibitory interaction (with N-CoR).
While our data suggest a role for p300 in the cyclindependent regulation of B-Myb activity the molecular basis of the stimulatory effect of p300 on B-Myb still needs to be clarified. The data obtained by using the HAT-deficient mutant of p300 are consistent with the idea that acetylation of B-Myb by p300 accounts for part of the stimulatory effect of p300. However, the finding that HAT-deficient p300 increases the activity of B-Myb half as strongly as wt p300 clearly indicates that the stimulatory effect of p300 is due both to acetylationdependent and acetylation-independent mechanisms. Further experiments addressing these mechanisms are in progress in our laboratory.
Materials and methods
Eukaryotic expression vectors
Expression vectors for full-length mouse B-Myb (pMuBMEx9A þ ) and for deletion mutants B-Myb D3 (pMuBMEx9a þ D3), B-Myb DEar (pMuBMDEar), B-Myb DApo (pMuBMDApo) and B-Myb DFsp (pMuBMDFsp) have been described before (Kamano and Klempnauer, 1997) . BMyb DSac (encoded by expression vector pMuBMDSac) is a truncated form of B-Myb lacking amino acids 561-704 from the C-terminus and was generated by truncating the B-Myb coding region at a SacI restrictions site located at the appropriate position. B-Myb mutants mut10 and mut15 have been described before (Johnson et al., 2002) and were a kind gift of RE Lewis. Expression vectors for Gal4/B-Myb fusion proteins Gal4/B-Myb D1, Gal4/B-Myb D2, Gal4/B-Myb D3, Gal4/B-Myb D4 and Gal4/B-Myb D5 have been described before (Horstmann et al., 2000a, b) . Expression vectors for human cyclin D1 (pRc/cycD1, Dowdy et al., 1993) and human cyclin A (pRc/cycA, Hinds et al., 1992) were obtained from R Weinberg. The p300 expression vector pCMV-p300CHA encodes full-length human p300 containing a C-terminal hemagglutinin tag and was a gift from R Eckner (Eckner et al., 1994) . The p300 HAT mutant p300HA-DI1485AL was obtained from A Hecht (Hecht et al., 2000) . The deletion mutants of human p300 pCDNA300-ATG-Xba, pCDNA300-SN13G/3 and pCDNA300-BPE were described elsewhere (Mink et al., 1997) . These vectors encode p300/1-1264, p300/ 1515-1998 and p300/1853-2414, respectively.
Reporter genes, transfections, luciferase and b-galactosidase assays
The Myb-inducible reporter plasmid pGL3-3xATk-Luc has been described (Horstmann et al., 2000b) . pCMVb was obtained from Clontech. QT6 cells were transfected as described . Luciferase and
The cooperation of B-Myb with the coactivator p300 S Schubert et al b-galactosidase reporter plasmids were transfected at 3 and 0.5 mg per 10 cm tissue culture dish, respectively. The amounts of expression vectors for B-Myb, p300 and cyclins A and D1 ranged from 1 to 5 mg per 10 cm tissue culture dish, depending on the experiment. Cells were harvested 24 h after transfection. Preparation of cell extracts, luciferase and b-galactosidase assays were performed as described (Horstmann et al., 2000b) .
GST fusion proteins and in vitro binding assay pGST/B-Myb-D3, pGST/B-Myb-DFsp, GST/p300(1-672), GST/p300(672-1193), GST/p300(1710-1891) and GST/ p300(1883-1927) have been described elsewhere (Horstmann et al., 2000a; Hasan et al., 2001; Schwartz et al., 2003) . GST fusion protein expression was induced in logarithmically growing cultures of transformed bacteria (E. coli BL21-lys) by adding isopropyl-b-D-thiogalactopyranoside (IPTG) to a final concentration of 0.5 mM. After additional 3 h of growth the bacteria were harvested by centrifugation for 10 min at 8000 rpm, resuspended in GST-Lysis-Buffer (50 mM Tris-HCl; pH 8.0; 150 mM NaCl; 1% Triton X-100; 1 mM DTT; 0.1 mM PMSF) and lysed by three freeze-thaw cycles and sonification. An extract of soluble protein was prepared by ultracentrifugation for 1 h at 45 000 rpm (SW 50.1 rotor). Extract containing 5-10 mg of GST fusion protein was then mixed with 50 ml of glutathione-sepharose (Pharmacia) and incubated at 41C for 1 h. Afterwards, the sepharose beads were washed three times with phosphate-buffered saline (PBS) and used for GST pulldown assays as follows. Human p300 deletion mutants were translated in vitro with the TNT translation system (Promega) using the plasmids pCDNA300-SN13G/3 and pCDNA300-BPE as templates and 10 mCi per sample of [ 35 S]methionine (specific activity 4800 Ci/mmol). All subsequent steps were carried out on ice. The translation mixture was diluted 10-fold with GEX-incubation buffer (20 mM HEPES, pH 7.8; 75 mM KCl; 0.1 mM EDTA; 2.5 mM MgCl 2 ; 1 mM DTT; 0.1% NP-40; 500 mg/ml bovine serum albumin) and cleared by centrifugation for 10 min at 14 000 rpm. A total of 50 ml of supernatant was then mixed with bacterially expressed GST fusion protein, coupled to 50 ml glutathione-sepharose, and incubated under constant agitation for 1 h at 41C. The sepharose beads were washed once with GEX incubation buffer, once with PBS containing 1% Triton X-100 and once with PBS. Finally, the proteins were eluted from the beads with sodium dodecyl sulfate (SDS) sample buffer and analysed by SDS-polyacrylamide gel electrophoresis (PAGE) and autoradiography. To analyse input protein samples one fifth of the amount of protein used for binding experiments was loaded directly onto the gel. GST-pull-down experiments with total cell extracts were performed as follows. QT6 cells transfected with the appropriate expression vectors were lysed in buffer containing 50 mM Tris-HCl, pH 7.5; 120 mM NaCl; 20 mM NaF; 1 mM EDTA; 6 mM EGTA; 15 mM sodiumpyrophosphate; 1 mM PMSF and 0.1% NP-40. Equal aliquots of the lysate were then incubated under constant agitation for 1 h at 41C with bacterially expressed GST fusion protein coupled to glutathione-sepharose. Washing of the sepharose beads and the analysis of the bound proteins was performed as described above, except that B-Myb was detected by Western blotting.
In vivo coimmunoprecipitation
To detect complexes of B-Myb and p300 in vivo, QT6 cells were transfected with the appropriate expression vectors. After 24 h, the cells were radiolabeled for 3 h with 100 mCi of [ 35 S]methionine per ml (specific activity 4800 Ci/mmol), washed with PBS, and lysed in ice-cold lysis buffer (10 mM Tris-HCl; pH 7.8; 50 mM NaCl; 0.5% sodium deoxycholate; 0.5% NP-40; 0.1% SDS). All subsequent steps were carried out on ice. After shearing the DNA with a syringe, insoluble material was removed by centrifugation for 30 min at 41C and 14 000 rpm. The supernatant was divided into two aliquots, and antibodies against the DNA-binding domain of mouse BMyb (Kamano et al., 1995) , the N-terminus of p300 (p300 N15, St Cruz Biotechnology) or the C-terminus of p300 (Upstate Biotechnology Inc., anti-p300 #05-267) were added, depending on the transfected DNA. After incubation overnight under constant agitation at 41C protein A sepharose or formaldehyde-fixed Staphylococcus aureus cells (Pansorbin, Calbiochem) were added, icubated for 1 h and washed three times with lysis buffer and once with PBS. Finally, the immunoprecipitated proteins were analysed by SDS-PAGE and autoradiography.
Western blotting
Immunostaining of mouse B-Myb proteins transferred to nitrocellulose was performed as described (Kamano et al., 1995) . B-Myb proteins were detected with a polyclonal rabbit antiserum raised against the B-Myb DNA-binding domain (Kamano et al., 1995) . p300-specific antibodies (anti-p300, #05-267) were obtained from Upstate Biotechnology, Inc. Antibodies specific for acetylated lysine (Ac-K-103) were obtained from Cell Signaling Technology. Anti cyclin D1 antibodies (H-295) were from St Cruz Biotechnology.
